The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)

Publications

Helman DL, Byrd JC, Ales NC, Shorr AF

Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes.

Chest 2002 Sep;122;785-90 — 2002 Sep — 785-90

Stoica GS, Greenberg HE, Rossoff LJ

Corticosteroid responsive fludarabine pulmonary toxicity.

American journal of clinical oncology 2002 Aug;25;340-1 — 2002 Aug — 340-1

Hurst PG, Habib MP, Garewal H, Bluestein M, Paquin M, Greenberg BR

Pulmonary toxicity associated with fludarabine monophosphate.

Investigational new drugs 1987;5;207-10 — 1987 — 207-10

Kane GC, McMichael AJ, Patrick H, Erslev AJ

Pulmonary toxicity and acute respiratory failure associated with fludarabine monophosphate.

Respiratory medicine 1992 May;86;261-3 — 1992 May — 261-3